Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24286073 | 0.77 | LRRK2 (0.44) | LRRK2ABL1 | |
| SCHEMBL24285831 | 0.77 | LRRK2 (0.48) | PIM1SRCGSK3ATGFBR1LRRK2 | |
| SCHEMBL24285941 | 0.74 | TDO2 (0.33) | TGFBR1ALDH1A1TGFBR2MTOR | |
| SCHEMBL25377922 | 0.73 | PIM1 (0.32) | PIM1SRCGSK3ATGFBR1LRRK2 | |
| SCHEMBL24286674 | 0.71 | DPP4 (0.40) | PIM1TGFBR1ALDH1A1USP7ABL1 | |
| SCHEMBL24285966 | 0.70 | MAP4K1 (0.34) | ALDH1A1USP7NPC1RAB9A | |
| SCHEMBL24286001 | 0.69 | ABL1 (0.42) | PIM1TGFBR1ALDH1A1ABL1NPC1 | |
| SCHEMBL24285985 | 0.69 | CDK2 (0.38) | TGFBR1ALDH1A1LRRK2ABL1 | |
| SCHEMBL24285836 | 0.68 | SLC2A1 (0.42) | TGFBR1ALDH1A1USP7ABL1NPC1 | |
| SCHEMBL24286093 | 0.68 | PIM1 (0.37) | PIM1SRCGSK3ATGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1ST Biotherapeutics, Inc. (KR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | NLRP3, NLRP1, KCNJ2 | PIM1 1243/4885SRC 2258/4885GSK3A 1778/4885 |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | NLRP3, NLRP1, KCNJ2 | PIM1 1243/4885SRC 2258/4885GSK3A 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.